DAVID S. GOLDSTEIN, M.D., Ph.D.; ROBIN STULL, B.S.; GRAEME EISENHOFER, Ph.D.; JAMES C. SISSON, M.D.; ALAN WEDER, M.D.; STEVEN D. AVERBUCH, M.D.; HARRY R. KEISER, M.D.
GOLDSTEIN DS, STULL R, EISENHOFER G, SISSON JC, WEDER A, AVERBUCH SD, et al. Plasma 3, 4-Dihydroxyphenylalanine (Dopa) and Catecholamines in Neuroblastoma or Pheochromocytoma. Ann Intern Med. 1986;105:887-888. doi: 10.7326/0003-4819-105-6-887
Download citation file:
Published: Ann Intern Med. 1986;105(6):887-888.
Neuroblastomas and benign and malignant pheochromocytomas are tumors of neural-crest origin that have different clinical characteristics: neuroblastomas are aggressive tumors that occur in children and have no association with hypertension, and pheochromocytomas are slow-growing tumors that occur in both adults and children and have an association with hypertension. Malignant and benign pheochromocytomas cannot be distinguished histologically; malignancies are defined by metastasis.
Consistent with their ontogeny, these tumors contain catecholamine precursors, catecholamines, and catecholamine metabolites. Urinary rates of excretion of these substances are key factors in tumor diagnosis. In human urine, the predominant free (unconjugated) catecholamine is dopamine, which probably is
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Hematology/Oncology, Adrenal Disorders, Endocrine Cancer.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only